Reply to: “Predictors of sorafenib benefit in patients with hepatocellular carcinoma”
Journal
Journal of Hepatology
Journal Volume
68
Journal Issue
3
Pages
620-621
Date Issued
2018
Author(s)
SDGs
Other Subjects
placebo; sorafenib; carbanilamide derivative; nicotinamide; sorafenib; cancer patient; cancer survival; comparative effectiveness; disease association; hepatitis B; Hepatitis B virus; human; Letter; liver cell carcinoma; nonhuman; priority journal; systemic therapy; liver cell carcinoma; liver tumor; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib
Publisher
Elsevier B.V.
Type
letter